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Characterization of micro‑RNA 
in women with different ovarian 
reserve
Masood Abu‑Halima1*, Lea Simone Becker1, Basim M. Ayesh2, Simona Lucia Baus3, 
Amer Hamza3,4, Ulrike Fischer1, Mohamad Hammadeh3, Andreas Keller5 & Eckart Meese1
Women undergoing infertility treatment are routinely subjected to one or more tests of ovarian 
reserve. Therefore, an adequate assessment of the ovarian reserve is necessary for the treatment. 
In this study, we aimed to characterize the potential role of microRNAs (miRNAs) as biomarkers for 
women with different ovarian reserves. A total of 159 women were recruited in the study and classified 
according to their anti‑Müllerian hormone (AMH) level into three groups: (1) low ovarian reserve 
(LAMH, n = 39), (2) normal ovarian reserve (NAMH, n = 80), and (3) high ovarian reserve (HAMH, n = 40). 
SurePrint Human miRNA array screening and reverse transcription‑quantitative PCR (RT‑qPCR) were 
respectively employed to screen and validate the miRNA abundance level in the three tested groups. 
Compared with NAMH, the abundance level of 34 and 98 miRNAs was found to be significantly altered 
in LAMH and HAMH, respectively. The abundance level of miRNAs was further validated by RT‑qPCR 
in both, the screening samples as well as in an independent set of validation samples. The abundance 
levels of the validated miRNAs were significantly correlated with the AMH level. The best AUC value 
for the prediction of the increase and decrease in the AMH level was obtained for the miR‑100‑5p and 
miR‑21‑5p, respectively. The level of miRNAs abundance correlates with the level of AMH, which may 
serve as a tool for identifying women with a different ovarian reserve and may help to lay the ground 
for the development of novel diagnostic approaches.
Assessment of the ovarian reserve has become essential to determine the strategy for the treatment of female 
infertility. For this purpose, several non-invasive clinical, endocrinological, and ultrasonographic examinations, 
at the early follicular phase, have been applied. Yet, to our best knowledge, no ideal test for ovarian reserve assess-
ment exists. Serum levels of anti-Müllerian hormone (AMH) and total antral follicle count (AFC) performed 
better than all other known markers, and are the most predictive, direct tests for evaluation of ovarian  reserve1. 
Currently, no molecular biomarkers are used, in combination with these conventional tests, to brush up the pre-
dictive accuracy of different forms of ovarian reserves. MicroRNAs (miRNAs) have received increasing attention 
due to their likely role in the regulation of nearly every cellular process. Currently, there are 2300 “real” miRNAs 
in the miRNA database based on miRBase.org2. Changes in miRNA abundance level are associated with many 
reproductive pathologies in both male and female  partners3–11. In the female partner, miRNAs were found to be 
involved in ovarian development and  function11. Specifically, the literature supports a crucial role for miRNAs 
during various stages in either somatic cells and/or ovarian follicles. In turn, a functional and crucial role in the 
production of the mature, and viable oocytes that are capable of fertilization and subsequent embryo develop-
ment and implantation of miRNA has been  suggested12–14. Circulating miRNAs have been utilized as a potential 
independent predictive system for different diseases due to their abundant and unique merits in body fluid (i.e., 
stable, easy to be detected, and potentially disease-specific)15,16. As miRNAs seem to be an important regulator 
of gene expression during follicular development and maturation, we hypothesized that circulating miRNAs in 
the early follicular phase could serve as potentially useful biomarkers for predicting ovarian reserve. To address 
this hypothesis, we characterized the abundance level of circulating miRNAs in women undergoing assisted 
reproductive technology (ART) using a large panel of human miRNA arrays. Then, we validated the deregulated 
miRNAs in a large independent cohort of samples with individual quantitative reverse transcriptase-polymerase 
chain reaction (RT-qPCR) assays. Data were analyzed to determine whether circulating miRNA profiles correlate 
OPEN
1Institute of Human Genetics, Saarland University, 66421 Homburg, Saar, Germany. 2Department of Laboratory 
Medical Sciences, Alaqsa University, Gaza, Palestine. 3Department of Obstetrics and Gynecology, Saarland 
University, 66421 Homburg, Saar, Germany. 4Kantonspital Baden, Im Ergel 1, 5400 Baden, Switzerland. 5Chair for 
Clinical Bioinformatics, Saarland University, 66123 Saarbruecken, Germany. *email: masood@daad-alumni.de
2
Vol:.(1234567890)
Scientific Reports |        (2021) 11:13351  | https://doi.org/10.1038/s41598-021-92901-w
www.nature.com/scientificreports/
with the level of serum AMH and can serve as potential biomarkers for predicting ovarian reserve in women 
attending infertility treatment.
Results
Study population. The demographic, hormonal, and clinical characteristics of the participating women 
presenting at an infertility clinic were collected and statistically evaluated. The women undergoing infertility 
treatment were classified according to the ovarian reserve into three groups; normal (n = 80), high (n = 40), and 
low (n = 39) based on AMH level as described by Antonio La Marca and  Sunkara1. As shown in Table 1, no sta-
tistically significant difference was observed between the groups in terms of their mean FT4 and TSH. However, 
a statistically significant difference was detected between the three groups in terms of the mean age, PRL, LH, 
FSH, Basal E2, Testosterone, Androstenedione, DHEA-S, and AFC (P < 0.05).
To determine which of the demographic, hormonal and clinical characteristics correlated directly with the 
AMH level, a spearman’s correlation was carried out. The serum level of AMH was negatively correlated with age 
(P = 0.001; r = − 0.49) and serum FSH concentration (P = 0.003; r = 0.45) and positively correlated with the AFC 
(P < 0.0001; r = 0.694). In addition, weak positive correlations were found between the serum concentrations of 
AMH and LH (P < 0.033; r = 0.34), Testosterone (P = 0.018; r = 0.37), and Androstenedione (P = 0.048; r = 0.31). 
No significant correlation was found between the serum concentration of AMH and basal E2, DHEA-S, PRL, 
and FT4 (Supplementary Table 1).
Screening of differentially abundant miRNAs using microarray. To identify miRNAs that are dif-
ferentially abundant in the blood samples of included women, we analyzed the abundance level of 2549 human 
mature miRNAs of miRBase v21. The abundance levels of circulating miRNAs were screened in 38 women 
including LAMH (n = 12), NAMH (n = 13), and HAMH (n = 13) (phase I). By considering the miRNAs with 
a significant adjusted P value of < 0.05 with fold change ≥ 2 (lower and higher abundant level), only 34 and 98 
miRNAs showed differential abundance levels in LAMH and HAMH groups, as compared to NAMH group, 
respectively (Fig. 1). As shown in Table 2, of the 34 differentially abundant miRNAs in LAMH versus NAMH, 
18 miRNAs were significantly lower and 16 miRNAs were significantly higher in the abundance level, whereas 
44 miRNAs were significantly lower, and 54 miRNAs were significantly higher in the HAMH versus NAMH 
group. The two abnormal groups i.e., LAMH versus HAMH were also compared with one another, however, no 
significantly differently abundant miRNA was identified (data not shown).
Validation of candidate miRNAs by RT‑qPCR. Using RT-qPCR, the validation of microarray data was 
performed to re-examine the abundance level of 74 miRNAs using the same samples, which have been used for 
the microarray experiments (phase II). These 74 miRNAs (as illustrated in Supplementary Fig. 1) were selected 
based on their differential abundance level in only LAMH (n = 7 miRNAs), only in HAMH (n = 46 miRNAs), and 
in both groups i.e., LAMH and HAMH (n = 21 miRNAs). As shown in Table 3 (phase II), RT-qPCR showed the 
same direction of abundance changes as the microarray analysis for 12 miRNAs, when comparing the samples 
from LAMH to NAMH (miR-144-5p, miR-7-1-3p, miR-126-3p, miR-146b-5p, miR-338-3p, miR-3200-3p, miR-
330-3p, miR-21-5p, miR-7-5p, miR-660-5p, miR-148b-3p, and miR-199b-5p). Significant changes in abundance 
were confirmed for these 12 down-regulated miRNAs (P < 0.05).
Similarly, RT-qPCR showed the same direction of abundance changes as the microarray analysis for 23 
miRNAs when comparing the samples from HAMH to NAMH (miR-3125, and miR-483-5p, miR-100-5p, miR-
3200-3p, miR-7-1-3p, miR-18a-5p, miR-17-3p, miR-133b, miR-654-3p, miR-221-3p, miR-18b-5p, miR-744-5p, 
Table 1.  Statistical evaluation of the demographic, hormonal and clinical characteristics of women presenting 
at an infertility clinic. n = 159. Grouping according to normal, high, and low ovarian reserve. ANOVA, 
mean ± standard deviation. Statistically significant if P value < 0.05. FT4 free thyroxine 4, TSH thyroid 
stimulating hormone, PRL prolactin, LH luteinizing hormone, FSH follicle stimulating hormone, Basal E2 
basal estradiol, DHEA-S dehydroepiandrosterone sulfate, AMH anti-Müllerian hormone, AFC antral follicle 
count.
Variable Normal response (n = 80) High response (n = 40) Low response (n = 39) P value
Age (year) 32 ± 0.50 30 ± 0.65 36 ± 0.61 0.0001
FT4 (ng/dL) 1.8 ± 0.30 1.4 ± 0.19 1.6 ± 0.36 0.6892
TSH (μIU/mL) 2.0 ± 0.17 2.2 ± 0.28 2.1 ± 0.20 0.7342
PRL (µIU/mL) 346 ± 17.0 311 ± 19 271 ± 16 0.0185
LH (mIU/mL) 6.2 ± 0.34 7.9 ± 0.68 8.1 ± 0.84 0.0221
FSH (mIU/mL) 7.1 ± 0.20 6.3 ± 0.23 14.0 ± 1.7 0.0001
Basal E2 (pg/mL) 40 ± 2.40 37 ± 3.00 54 ± 4.9 0.0012
Total Testosterone (ng/mL) 0.25 ± 0.017 0.38 ± 0.024 0.19 ± 0.015 0.0001
Androstenedione (ng/mL) 1.7 ± 0.09 2.4 ± 0.18 1.2 ± 0.09 0.0001
DHEA-S (ng/mL) 1705 ± 101 1905 ± 154 1388 ± 113 0.0304
AMH (ng/mL) 2.6 ± 0.11 7.3 ± 0.33 0.51 ± 0.05 0.0001
AFC 11 ± 0.71 20 ± 1.5 5.0 ± 0.43 0.0001
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:13351  | https://doi.org/10.1038/s41598-021-92901-w
www.nature.com/scientificreports/
miR-10a-5p, miR-28-5p, miR-181a-2-3p, miR-330-3p, miR-660-5p, miR-183-5p, miR-199b-5p, miR-505-3p, miR-
148b-3p, miR-199a-5p, and miR-23b-3p) (Table 3, phase II). Significant changes in abundance were confirmed 
for 2 miRNAs with higher abundance levels and 21 miRNAs with lower abundance levels (P < 0.05).
Further validation of the identified miRNAs was conducted by using a cohort of independent samples (phase 
III). Women with low (n = 27), high (n = 27), and normal (n = 67) levels of AMH level were included. As for the 
validation step, the RT-qPCR confirmed the direction of abundance changes and the significance of different 
abundances between LAMH and NAMH for 10 miRNAs (miR-144-5p, miR-7-1-3p, miR-126-3p, miR-146b-5p, 
miR-338-3p, miR-3200-3p, miR-330-3p, miR-21-5p, miR-7-5p, and miR-660-5p (P < 0.05) (Table 3). Additionally, 
out of the 23 identified miRNAs in the phase II between HAMH and NAMH groups, 15 miRNAs including miR-
100-5p, miR-3200-3p, miR-7-1-3p, miR-18a-5p, miR-17-3p, miR-133b, miR-221-3p, miR-18b-5p, miR-744-5p, 
miR-10a-5p, miR-28-5p, miR-330-3p, miR-660-5p, miR-183-5p, and miR-148b-3p showed a significantly lower 
abundance level in HAMH compared to NAMH (P < 0.05) (Table 3).
Moreover, 4 miRNAs (miR-502-5p, miR-27a-3p, miR-374b-5p, and miR-140-5p) and 9 miRNAs (miR-27a-3p, 
miR-148a-3p, miR-7-5p, miR-96-5p, miR-500b-5, miR-144-5p, miR-140-5p, miR-338-3p, and miR-182-5p) were 
validated only in the independent sample set by RT-qPCR (phase III), when the number of samples have been 
increased (Table 3). By considering only the miRNAs which have been validated in phase III, we noticed that 
some miRNAs were deregulated in either one group (either LAMH or HAMH) or both groups (shared miRNAs) 
compared to NAMH. Specifically, 5 miRNAs were differentially abundant in only LAMH versus the NAMH 
group, 15 miRNAs in only HAMH versus NAMH group, and 9 miRNAs were shared in both groups (Fig. 1). 
When the two groups LAMH and HAMH were compared with one another, no significant difference in the 
abundance level was found, by using RT-qPCR either (data not shown).
Correlation of the validated miRNAs with age and AMH. A woman’s fertility gradually declines with 
age and this decline significantly correlates with the number and quality of her eggs. To exclude the age-related 
changes in miRNA abundance level, correlation analysis between the validated miRNA abundance levels (phase 
III, i.e., 29 miRNAs) (Fig. 1) and the age of the included women was performed. As shown in Fig. 2A, the miRNA 
abundance levels were shifted slightly towards older women with lower AMH levels (i.e., women with poor ovar-
ian reserve) and were shifted slightly towards younger women with higher AMH levels. However, this slight shift 
in the abundance level of miRNAs was not significantly correlated to age, suggesting that the altered abundance 
level of miRNAs that we observed occurs regardless of age, as depicted in Fig. 2B. In contrast to age, the validated 
miRNA abundance levels (phase III, i.e., 29 miRNAs) in the LAMH, HAMH, and NAMH were mostly abundant 
in the range of low, high and normal AMH concentrations, respectively, as shown in Fig. 2C. To prove that the 
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Figure 1.  Workflow chart showing the number of women enrolled and the number and regulation of the 
detected miRNAs by microarray and RT-qPCR analyses.
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miRBase Accession Nr MicroRNA Adjusted P value P value Log2 FC Regulation
LAMH (n = 12) compared to NAMH group (n = 13)
MIMAT0004600 miR-144-5p 0.0309 0.0038 − 3.69 Lower
MIMAT0004955 miR-374b-5p 0.0370 0.0063 − 3.38 Lower
MIMAT0004553 miR-7-1-3p 0.0259 0.0005 − 3.33 Lower
MIMAT0000431 miR-140-5p 0.0413 0.0087 − 3.02 Lower
MIMAT0000445 miR-126-3p 0.0475 0.0134 − 2.96 Lower
MIMAT0002809 miR-146b-5p 0.0273 0.0010 − 2.77 Lower
MIMAT0000763 miR-338-3p 0.0308 0.0027 − 2.74 Lower
MIMAT0015085 miR-3200-3p 0.0390 0.0069 − 2.62 Lower
MIMAT0005796 miR-1271-5p 0.0390 0.0078 − 2.19 Lower
MIMAT0004586 miR-15b-3p 0.0475 0.0127 − 2.10 Lower
MIMAT0002873 miR-502-5p 0.0274 0.0018 − 2.10 Lower
MIMAT0000084 miR-27a-3p 0.0309 0.0032 − 2.10 Lower
MIMAT0000263 miR-199b-5p 0.0475 0.0126 − 1.48 Lower
MIMAT0000751 miR-330-3p 0.0494 0.0145 − 1.29 Lower
MIMAT0000759 miR-148b-3p 0.0309 0.0038 − 1.17 Lower
MIMAT0000076 miR-21-5p 0.0278 0.0020 − 1.17 Lower
MIMAT0000252 miR-7-5p 0.0273 0.0012 − 1.16 Lower
MIMAT0003338 miR-660-5p 0.0273 0.0016 − 1.10 Lower
MIMAT0022694 miR-211-3p 0.0118 0.0001 4.38 Higher
MIMAT0019835 miR-4721 0.0007 0.0000 4.29 Higher
MIMAT0005942 miR-1288-3p 0.0273 0.0014 3.38 Higher
MIMAT0027460 miR-6780a-5p 0.0273 0.0013 3.31 Higher
MIMAT0027514 miR-6807-5p 0.0308 0.0027 3.27 Higher
MIMAT0019771 miR-4685-5p 0.0308 0.0024 3.11 Higher
MIMAT0025480 miR-6512-5p 0.0308 0.0030 3.08 Higher
MIMAT0003240 miR-575 0.0318 0.0041 2.93 Higher
MIMAT0014990 miR-3127-5p 0.0475 0.0127 2.82 Higher
MIMAT0025855 miR-6723-5p 0.0475 0.0120 2.72 Higher
MIMAT0015030 miR-3156-5p 0.0309 0.0038 2.58 Higher
MIMAT0021125 miR-5194 0.0390 0.0074 2.36 Higher
MIMAT0024599 miR-6126 0.0475 0.0126 2.35 Higher
MIMAT0004982 miR-939-5p 0.0425 0.0099 2.14 Higher
MIMAT0022275 miR-5581-5p 0.0475 0.0135 2.10 Higher
MIMAT0027434 miR-6767-5p 0.0475 0.0137 2.08 Higher
HAMH (n = 13) compared to NAMH group (n = 13)
MIMAT0000098 miR-100-5p 0.0453 0.0309 − 3.73 Lower
MIMAT0015085 miR-3200-3p 0.0262 0.0010 − 3.00 Lower
MIMAT0022482 miR-5690 0.0262 0.0021 − 2.95 Lower
MIMAT0004553 miR-7-1-3p 0.0263 0.0044 − 2.87 Lower
MIMAT0000095 miR-96-5p 0.0437 0.0165 − 2.67 Lower
MIMAT0016925 miR-500b-5p 0.0282 0.0054 − 2.67 Lower
MIMAT0004600 miR-144-5p 0.0453 0.0312 − 2.67 Lower
MIMAT0003258 miR-590-5p 0.0453 0.0226 − 2.65 Lower
MIMAT0000431 miR-140-5p 0.0453 0.0178 − 2.60 Lower
MIMAT0000763 miR-338-3p 0.0363 0.0089 − 2.48 Lower
MIMAT0000259 miR-182-5p 0.0363 0.0089 − 2.34 Lower
MIMAT0002873 miR-502-5p 0.0262 0.0023 − 2.32 Lower
MIMAT0004560 miR-183-3p 0.0262 0.0034 − 2.29 Lower
MIMAT0000072 miR-18a-5p 0.0453 0.0284 − 2.28 Lower
MIMAT0000071 miR-17-3p 0.0453 0.0360 − 2.24 Lower
MIMAT0000770 miR-133b 0.0453 0.0323 − 2.23 Lower
MIMAT0004814 miR-654-3p 0.0453 0.0385 − 2.13 Lower
MIMAT0004586 miR-15b-3p 0.0453 0.0196 − 2.11 Lower
MIMAT0000278 miR-221-3p 0.0474 0.0490 − 2.06 Lower
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miRBase Accession Nr MicroRNA Adjusted P value P value Log2 FC Regulation
MIMAT0000689 miR-99b-5p 0.0453 0.0315 − 1.99 Lower
MIMAT0004945 miR-744-5p 0.0453 0.0277 − 1.98 Lower
MIMAT0000084 miR-27a-3p 0.0363 0.0090 − 1.96 Lower
MIMAT0005593 miR-1238-3p 0.0453 0.0314 − 1.89 Lower
MIMAT0000257 miR-181b-5p 0.0462 0.0412 − 1.84 Lower
MIMAT0000426 miR-132-3p 0.0387 0.0121 − 1.83 Lower
MIMAT0000253 miR-10a-5p 0.0453 0.0356 − 1.81 Lower
MIMAT0000085 miR-28-5p 0.0453 0.0180 − 1.67 Lower
MIMAT0004558 miR-181a-2-3p 0.0453 0.0389 − 1.60 Lower
MIMAT0017392 miR-3200-5p 0.0282 0.0054 − 1.49 Lower
MIMAT0000243 miR-148a-3p 0.0453 0.0197 − 1.41 Lower
MIMAT0004810 miR-629-5p 0.0453 0.0378 − 1.39 Lower
MIMAT0000252 miR-7-5p 0.0262 0.0008 − 1.31 Lower
MIMAT0000751 miR-330-3p 0.0370 0.0111 − 1.29 Lower
MIMAT0000279 miR-222-3p 0.0453 0.0215 − 1.27 Lower
MIMAT0003338 miR-660-5p 0.0394 0.0131 − 1.26 Lower
MIMAT0000452 miR-154-5p 0.0453 0.0388 − 1.25 Lower
MIMAT0000261 miR-183-5p 0.0262 0.0035 − 1.21 Lower
MIMAT0000263 miR-199b-5p 0.0480 0.0502 − 1.19 Lower
MIMAT0002876 miR-505-3p 0.0465 0.0477 − 1.18 Lower
MIMAT0019923 miR-4769-3p 0.0495 0.0528 − 1.09 Lower
MIMAT0000759 miR-148b-3p 0.0372 0.0114 − 1.09 Lower
MIMAT0000231 miR-199a-5p 0.0262 0.0029 − 1.05 Lower
MIMAT0000418 miR-23b-3p 0.0462 0.0454 − 1.04 Lower
MIMAT0019835 miR-4721 0.0262 0.0009 3.91 Higher
MIMAT0022694 miR-211-3p 0.0282 0.0052 3.29 Higher
MIMAT0005942 miR-1288-3p 0.0262 0.0032 3.17 Higher
MIMAT0027460 miR-6780a-5p 0.0282 0.0056 2.96 Higher
MIMAT0027470 miR-6785-5p 0.0462 0.0442 2.67 Higher
MIMAT0027514 miR-6807-5p 0.0393 0.0128 2.64 Higher
MIMAT0022942 miR-1229-5p 0.0453 0.0353 2.59 Higher
MIMAT0022271 miR-664b-5p 0.0453 0.0368 2.50 Higher
MIMAT0019849 miR-4728-5p 0.0370 0.0109 2.49 Higher
MIMAT0002877 miR-513a-5p 0.0453 0.0265 2.49 Higher
MIMAT0024599 miR-6126 0.0437 0.0160 2.42 Higher
MIMAT0019871 miR-4741 0.0453 0.0308 2.38 Higher
MIMAT0003240 miR-575 0.0453 0.0312 2.30 Higher
MIMAT0025480 miR-6512-5p 0.0453 0.0301 2.28 Higher
MIMAT0005948 miR-664a-5p 0.0453 0.0283 2.27 Higher
MIMAT0014988 miR-3125 0.0462 0.0434 2.25 Higher
MIMAT0022286 miR-5585-3p 0.0363 0.0102 2.24 Higher
MIMAT0025855 miR-6723-5p 0.0453 0.0357 2.24 Higher
MIMAT0014990 miR-3127-5p 0.0453 0.0368 2.22 Higher
MIMAT0015030 miR-3156-5p 0.0453 0.0263 2.03 Higher
MIMAT0025476 miR-6510-5p 0.0453 0.0256 2.02 Higher
MIMAT0021033 miR-5006-5p 0.0453 0.0261 1.98 Higher
MIMAT0021125 miR-5194 0.0465 0.0477 1.91 Higher
MIMAT0018072 miR-3652 0.0323 0.0071 1.89 Higher
MIMAT0027355 miR-6727-5p 0.0475 0.0494 1.85 Higher
MIMAT0004761 miR-483-5p 0.0453 0.0263 1.81 Higher
MIMAT0019749 miR-4669 0.0453 0.0340 1.80 Higher
MIMAT0027524 miR-6812-5p 0.0453 0.0278 1.78 Higher
MIMAT0019035 miR-4499 0.0453 0.0256 1.76 Higher
MIMAT0027566 miR-6833-5p 0.0453 0.0317 1.74 Higher
MIMAT0016852 miR-4298 0.0453 0.0261 1.73 Higher
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out. A significant correlation was observed for 26 out of 29 miRNAs in LAMH versus NAMH and HAMH versus 
NAMH (Fig. 2D). Of these correlated miRNAs, 7 miRNAs were correlated with AMH level in the LAMH versus 
NAMH group and 14 miRNAs in HAMH versus NAMH group. While 5 miRNAs were correlated with AMH in 
both tested groups i.e., LAMH versus NAMH and HAMH versus NAMH. These findings provide evidence that 
the miRNA abundance levels changed significantly in the groups, depending on the level of AMH.
Additionally, miR-144-5p and miR-140-5p that were previously shared in both groups (i.e., LAMH and 
HAMH, Fig. 1) were found to be correlated with AMH level in only LAMH versus NAMH. Similarly, miR-7-1-3p 
and miR-27a-3p were previously shared in both (i.e., LAMH and HAMH, Fig. 1), were found to be correlated 
with AMH level in only HAMH versus NAMH. Interestingly, the abundance level of miRNAs that were positively 
correlated with AMH in the LAMH versus NAMH is negatively correlated with the AMH in the HAMH versus 
NAMH (Fig. 2D, P < 0.05).
Diagnostic accuracy of the validated miRNAs. The miRNAs that have been validated in phase III by 
RT-qPCR and correlated with AMH level (26 miRNAs, Fig. 2D, Supplementary Fig. 2) were tested for their suit-
ability as biomarkers for assessing the ovarian reserve of a woman presenting at an infertility clinic. The receiver 
operating curve (ROC) analysis was performed, in which the miRNAs were tested for their predictive ability to 
detect women with low, normal, and high-ovarian reserve. All identified miRNAs that correlated with AMH 
have an AUC > 0.5. The best AUC value was observed for the miR-100-5p for the prediction of an increased 
AMH level with an AUC = 0.756. The calculated AUC values for the validated miRNAs correlated with AMH 
are shown in Fig. 2D.
Discussion
In this study, the difference in miRNA abundance level was determined in women with normal, low, and 
high ovarian reserve by miRNA microarray and RT-qPCR analyses. Considering miRNAs with an adjusted P 
value < 0.05 exhibiting ≥ 2-fold change in abundance level, the abundance level of 34 and 98 miRNAs was sig-
nificantly altered in the high (HAMH) and low LAMH groups, respectively, as compared to the normal NAMH 
group. The result was validated by RT-qPCR for 12 and 23 miRNAs in the LAMH and HAMH groups, respec-
tively. Using an independent set of samples, 14 and 24 miRNAs were validated in LAMH and HAMH groups, 
respectively (Fig. 1). Despite that the mean age of the three groups differed significantly, statistical analysis indi-
cated that no significant correlation exists between the abundance level of the validated miRNAs and the age of 
women in the three tested groups (Fig. 2B). On the other hand, the abundance level of the validated miRNAs was 
miRBase Accession Nr MicroRNA Adjusted P value P value Log2 FC Regulation
MIMAT0018943 miR-4428 0.0462 0.0441 1.66 Higher
MIMAT0004918 miR-892b 0.0462 0.0424 1.65 Higher
MIMAT0019791 miR-4697-5p 0.0453 0.0311 1.61 Higher
MIMAT0022945 miR-1236-5p 0.0453 0.0293 1.46 Higher
MIMAT0027450 miR-6775-5p 0.0453 0.0333 1.45 Higher
MIMAT0019691 miR-4634 0.0453 0.0364 1.45 Higher
MIMAT0030999 miR-8072 0.0437 0.0162 1.44 Higher
MIMAT0027638 miR-6869-5p 0.0453 0.0338 1.38 Higher
MIMAT0018981 miR-4459 0.0453 0.0266 1.35 Higher
MIMAT0023701 miR-6076 0.0453 0.0320 1.35 Higher
MIMAT0005929 miR-1275 0.0363 0.0091 1.33 Higher
MIMAT0002816 miR-494-3p 0.0370 0.0108 1.33 Higher
MIMAT0019965 miR-4793-5p 0.0453 0.0363 1.30 Higher
MIMAT0027650 miR-6875-5p 0.0262 0.0009 1.30 Higher
MIMAT0027572 miR-6780b-5p 0.0262 0.0006 1.29 Higher
MIMAT0032116 miR-4485-5p 0.0262 0.0032 1.22 Higher
MIMAT0005880 miR-1290 0.0495 0.0528 1.21 Higher
MIMAT0029782 miR-7641 0.0262 0.0017 1.20 Higher
MIMAT0009448 miR-1973 0.0462 0.0444 1.09 Higher
MIMAT0027398 miR-6749-5p 0.0262 0.0013 1.05 Higher
MIMAT0015079 miR-3195 0.0263 0.0042 1.04 Higher
MIMAT0024597 miR-6124 0.0262 0.0015 1.01 Higher
Table 2.  Significantly abundant miRNAs in the blood of women presenting at an infertility clinic as 
determined by microarray (adjusted P < 0.05 and fold change ≥ 2). LAMH (n = 12) compared to NAMH group 
(n = 13) and HAMH (n = 13) compared to NAMH group (n = 13). Unpaired t test was used to calculate the P 
value. Benjamini–Hochberg correction for multiple testing was used to adjust the P value. Significant changes 
in abundance levels are shown with an adjusted P value < 0.05 and log2 fold change. LAMH  low anti-Müllerian 
hormone levels,  HAMH high anti-Müllerian hormone levels, NAMH normal anti-Müllerian hormone level.
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Table 3.  Validation of the abundant miRNAs in the blood of women presenting at an infertility clinic as 
determined by RT-qPCR (P < 0.05). LAMH (n = 12) compared to NAMH group (n = 13), HAMH (n = 13) 
compared to NAMH group (n = 13), LAMH (n = 27) compared to NAMH group (n = 67), and HAMH (n = 27) 
compared to NAMH group (n = 67). Unpaired t-test was used to calculate the P value. Benjamini–Hochberg 
correction for multiple testing was used to adjust the P value. P values of < 0.05 was considered statistically 
significant. Relative abundance level of  2_ΔΔCt was used for RT-qPCR. LAMH low anti-Müllerian hormone, 
HAMH high anti-Müllerian hormone, NAMH normal anti-Müllerian hormone, FC fold change. a Additional 
miRNAs were only detected by RT-qPCR in the independent validation phase and were not previously 
detected by microarray in the screening phase.
LAMH (n = 12) compared to NAMH group (n = 13) LAMH (n = 27) compared to NAMH group (n = 67)
Phase II—Validation of screening phase by RT-qPCR Phase III—Independent validation by RT-qPCR
MicroRNA P value Log2 FC Regulation MicroRNA P value Log2 FC Regulation
miR-144-5p 0.0297 − 1.90 Lower miR-144-5p 0.0102 − 1.66 Lower
miR-7-1-3p 0.0138 − 1.62 Lower miR-7-1-3p 0.0365 − 0.71 Lower
miR-126-3p 0.0083 − 1.51 Lower miR-126-3p 0.0112 − 1.65 Lower
miR-146b-5p 0.0025 − 1.26 Lower miR-146b-5p 0.0282 − 0.71 Lower
miR-338-3p 0.0116 − 1.41 Lower miR-338-3p 0.0064 − 1.11 Lower
miR-3200-3p 0.0225 − 3.02 Lower miR-3200-3p 0.0264 − 2.09 Lower
miR-330-3p 0.0206 − 1.55 Lower miR-330-3p 0.0309 − 1.33 Lower
miR-21-5p 0.0076 − 1.53 Lower miR-21-5p 0.0111 − 1.45 Lower
miR-7-5p 0.0120 − 2.20 Lower miR-7-5p 0.0049 − 1.47 Lower
miR-660-5p 0.0090 − 1.21 Lower miR-660-5p 0.0225 − 0.85 Lower
miR-148b-3p 0.0011 − 1.99 Lower
miR-199b-5p 0.0355 − 1.33 Lower miRNAs detected only in the independent sample seta
miR-502-5p 0.0339 − 1.36 Lower
miR-27a-3p 0.0037 − 1.05 Lower
miR-374b-5p 0.0285 − 1.01 Lower
miR-140-5p 0.0144 − 1.15 Lower
HAMH (n = 13) compared to NAMH group (n = 13)
HAMH (n = 27) compared to NAMH group 
(n = 67)
Phase II—Validation of Screening phase by RT-qPCR Phase III—Independent validation by RT-qPCR
MicroRNA P value Log2 FC Regulation MicroRNA P value Log2 FC Regulation
miR-3125 0.0139 1.74 Higher miR-100-5p 0.0006 − 2.67 Lower
miR-483-5p 0.0028 2.18 Higher miR-3200-3p 0.0003 − 3.25 Lower
miR-100-5p 0.0001 − 3.87 Lower miR-7-1-3p 0.0001 − 1.45 Lower
miR-3200-3p 0.0274 − 3.06 Lower miR-18a-5p 0.0042 − 2.00 Lower
miR-7–1-3p 0.0279 − 1.49 Lower miR-17-3p 0.0394 − 1.44 Lower
miR-18a-5p 0.0146 − 1.97 Lower miR-133b 0.0091 − 1.18 Lower
miR-17-3p 0.0226 − 1.43 Lower miR-221-3p 0.0046 − 1.34 Lower
miR-133b 0.0281 − 1.70 Lower miR-18b-5p 0.0120 − 1.78 Lower
miR-654-3p 0.0412 − 1.27 Lower miR-744-5p 0.0076 − 0.65 Lower
miR-221-3p 0.0194 − 1.68 Lower miR-10a-5p 0.0310 − 0.78 Lower
miR-18b-5p 0.0063 − 2.02 Lower miR-28-5p 0.0001 − 1.37 Lower
miR-744-5p 0.0201 − 0.60 Lower miR-330-3p 0.0008 − 1.69 Lower
miR-10a-5p 0.0062 − 1.52 Lower miR-660-5p 0.0115 − 1.02 Lower
miR-28-5p 0.0059 − 1.36 Lower miR-183-5p 0.0019 − 1.41 Lower
miR-181a-2-3p 0.0003 − 1.92 Lower miR-148b-3p 0.0008 − 1.53 Lower
miR-330-3p 0.0107 − 1.87 Lower
miR-660-5p 0.0380 − 0.93 Lower miRNAs detected only in the independent sample seta
miR-183-5p 0.0155 − 1.47 Lower miR-27a-3p 0.0001 − 1.70 Lower
miR-199b-5p 0.0050 − 2.93 Lower miR-148a-3p 0.0090 − 1.49 Lower
miR-505-3p 0.0114 − 1.69 Lower miR-7-5p 0.0035 − 1.57 Lower
miR-148b-3p 0.0125 − 1.39 Lower miR-96-5p 0.0151 − 0.91 Lower
miR-199a-5p 0.0349 − 1.52 Lower miR-500b-5p 0.0000 − 1.20 Lower
miR-23b-3p 0.0425 − 1.06 Lower miR-144-5p 0.0108 − 1.80 Lower
miR-140-5p 0.0270 − 1.11 Lower
miR-338-3p 0.0002 − 1.55 Lower
miR-182-5p 0.0002 − 3.16 Lower
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significantly correlated with the AMH level in the tested groups (Fig. 2D). Accordingly, we may argue that the 
changes in miRNA abundance level have resulted from differences in the AMH level rather than differences in 
the women’s age. A statistically significant difference was observed between the three groups in terms of the mean 
age, PRL, LH, FSH, Basal E2, Testosterone, Androstenedione, DHEA-S, and AFC. Low levels of FSH and Basal 
E2 were found to correlate with improved ovarian  response17. Higher levels of LH and testosterone contribute to 
early ovarian reserve  failure18,19, while PRL could directly act on the ovary to suppress follicular  development20. 
Additionally, higher level of PRL have been correlated with menstrual disorders because of its restraining effect 
on pulsatile Gonadotropin-releasing hormone (GnRH) secretion as well as inhibition of FSH and LH  release21.
Our results concord with previous reports showing that many of our dysregulated miRNAs play a role in 
female reproduction and/or infertility-associated diseases of women and/or her male  partner3–11. In more details, 
MiR-330-3p, miR-144-5p, and miR-221-3p showed lower abundance levels in the cumulus cells of women with 
polycystic ovary syndrome (PCOS)22, and miR-144-5p and miR-133b expression in the granulosa cells and was 
linked to female  infertility23. In particular, miR-144-5p inhibits prostaglandin E2 (PGE2) secretion, which is an 
important regulator of ovulation and can therefore lead to fertility problems through changes in its  synthesis24. 
Xiao et al. found a higher abundance level of miR-133b in meiosis I oocytes when the insulin-like growth factor-I 
(IGF-1) was  overexpressed25. IGF-1 is involved in the development of the primordial follicles and the growth of 
the  oocytes25,26. The abundance level of miR-140-5p was significantly decreased in the follicular fluid of women 
with PCOS as compared to  controls27. Regulation of miR-140-5p by the Estrogen receptor α (ERα) was detected 
in women with breast cancer and in women with  PCOS27,28. Similarly, miR-126-3p was also associated with 
 PCOS29. The hypermethylation in the promoter site of the miR-126-3p gene was found in granulosa cells of 
patients with PCOS, which resulted in a reduction of the abundance level of miR-126-3p29. Another two miR-
NAs, namely miR-148a-3p and miR-28-5p were associated with  endometriosis30,31. As for miR-148a-3p, He et al. 
identified it as a modulator for the Estrogen  (E2)‐induced epithelial‐mesenchymal transition (EMT), which leads 
to  endometriosis31. Besides, Liu et al. found that the reduced abundance level of miR-148a-3p leads to the higher 
abundance level of its target gene, the small nucleolar RNA host gene 4 (SNHG4), and thus has a direct influence 
on the ectopic growth of the endometrium outside the  uterus32. As for miR-28-5p, Vanhie et al. concluded that 
miR-28-5p can be used as a non-invasive biomarker for endometriosis in infertile  women30. Additionally, miR-
28-5p was involved in the pathogenesis of PCOS via its target gene prokineticin 1 (PROK1) which plays a role in 
ovarian physiology, implantation of embryos in the endometrium, and success of  pregnancies33.












































miRNA r P value AUC
miR-146b-5p 0.38 0.0001 0.679
miR-21-5p 0.35 0.0001 0.693
miR-126-3p 0.34 0.0001 0.675
miR-144-5p 0.26 0.0045 0.651
miR-502-5p 0.27 0.0030 0.642
miR-140-5p 0.23 0.0107 0.621
miR-374b-5p 0.20 0.0270 0.605
miRNA LAMH/NAMH HAMH/NAMH AUCr P value r P value
miR-338-3p 0.34 0.0001 -0,23 0.0115 0.703
miR-3200-3p 0.30 0.0013 -0,25 0.0080 0.694
miR-7-5p 0.27 0.0037 -0,24 0.0095 0.681
miR-330-3p 0.28 0.0020 -0,19 0.0431 0.673
miR-660-5p 0.22 0.0144 -0,20 0.0254 0.659
miRNA r P value AUC
miR-100-5p -0,32 0.0004 0.756
miR-71-3p -0,34 0.0002 0.724
miR-27a-3p -0,32 0.0005 0.712
miR-500b-5p -0,26 0.0040 0.699
miR-182-5p -0,29 0.0014 0.716
miR-744-5p -0,28 0.0017 0.703
miR-10a-5p -0,26 0.0053 0.693
miR-28-5p -0,30 0.0010 0.739
miR-183-5p -0,24 0.0092 0.701
miR-148b-3p -0,25 0.0067 0.710
miR-18a-5p -0,19 0.0434 0.683
miR-133b -0,21 0.0280 0.676
miR-221-3p -0,20 0.0315 0.676
miR-148a-3p -0,23 0.0130 0.674
B
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Figure 2.  (A) Differences in the miRNA abundance level based on age, (B) correlation analysis of the 
differentially abundant miRNAs, which were validated exclusively in LAMH versus NAMH and HAMH versus 
NAMH with age, (C) Differences in the miRNA abundance level based on AMH (ng/ml), (D) Correlation 
analysis of the differentially abundant miRNAs, which were validated exclusively in LAMH versus NAMH and 
HAMH versus NAMH with AMH. Spearman’s correlation; r, correlation coefficient; statistically significant if P 
value < 0.05. LAMH low anti-Müllerian hormone, HAMH high anti-Müllerian hormone, NAMH normal anti-
Müllerian hormone, AMH anti-Müllerian hormone.
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MiR-21-5p was associated with the female reproductive system in many ways, besides its role in various 
types of cancer, such as  breast34,  ovarian35, and cervical  cancer36. MiR-21-5p has been associated with diseases 
that affect female fertility including the development of endometriosis, PCOS, and primary ovarian insuffi-
ciency (POI). In-depth, miR-21-5p was found to promote angiogenesis associated with the development of 
 endometriosis37. Park et al. observed an up-regulation of miR-21-5p in endometrial  cells38, while Papari et al. 
found a reduced expression level of miR-21-5p in the plasma of women with  endometriosis39. A physiological 
reduction in miR-21-5p was observed in human endometrial stromal cells (hESC) in preparation for preg-
nancy (decidualization)40. The abundance level of miR-21-5p was also investigated when the ovarian reserve 
was changed. Karakaya et al. found a higher abundance level of miR-21-5p in cumulus cells of women with low 
ovarian reserve (poor responder) presenting at an infertility clinic, while the abundance level of miR-21-3p was 
 lower41, suggesting that elevated miR-21-5p abundance level in cumulus cells is not regulated at the pre-miR-21 
level in women with low ovarian reserve. Very recently, a reduction in miR-21-5p abundance level was observed 
in the plasma of infertile women with abnormal AMH  levels42. Overall, it became clear that the miR-21-5p is 
changed in many processes that are related to the ovarian reserve. It can be assumed that miR-21-5p is a key 
regulator of female fertility.
MiR-100-5p has recently been identified as a potential biomarker for various female reproduction disorders, 
in ectopic  pregnancies43,  endometriosis44, recurrent implantation  failure45, and decreased ovarian  reserve46. 
A lower expression level of miR-100-5p was found in women with ectopic pregnancies compared to that in 
normal  pregnancies43. Similarly, a reduction in miR-100-5p expression level was observed in serum and plasma 
of women with unsuccessful embryo transfer compared to successful embryo  transfer45, suggesting that miR-
100-5p, may serve as a potential biomarker for recurrent miscarriage and/or recurrent implantation  failure38. 
Woo et al. also observed a reduction in miR-100-5p expression level in granulosa cells of women with diminished 
ovarian  response46 and reported that miR-100-5p targets fibroblast growth factor receptor 3 (FGFR3), insulin-
like growth factor 1 receptor (IGF1R), and cyclin E and cyclin-dependent kinase (CDK), which play a role in 
the proliferation and steroidogenesis of granulosa cells. Therefore, Woo et al. concluded that miR-100-5p limits 
the proliferation of granulosa cells by binding to these target genes. In agreement with our finding, miR-100-5p 
decreased in abundance in women with lower and higher ovarian reserve compared to normal suggesting that 
this miRNA can be used as a biomarker for ovarian reserve in women undergoing infertility treatment. Based 
on these studies, our finding of an altered abundance of miRNAs (especially MiR-21-5p and miR-100-5p) in 
women with reduced or increased ovarian reserve suggests that they may be involved in the pathogenesis of 
the condition and lay the ground for the development of novel diagnostic approaches for women manifesting 
diminished ovarian reserve and subsequent fertility complications.
Various parameters and biomedical markers have been proposed to detect the ovarian reserve including age, 
FSH, Estradiol, Inhibin, AMH, and  AFC1,47. Of these markers, AFC and AMH levels have been considered good 
predictors of the ovarian reserve during ART compared with other traditional  measures1,47–50. AMH level was 
observed to be highly correlated with the AFC, age, and basal FSH  level1,49. Therefore, AMH has been labelled 
as an adequate predictor of the ovarian reserve before IVF/ICSI treatment, in both, high and poor ovarian 
 responders1,47–50. Although the AMH level is highly correlated with the AFC, in clinical practice there is a dis-
crepancy between the AMH level and the AFC in about 18–32% of women presenting at an infertility  clinic48,51. In 
our study, due to the controversial discussion over the decades between the AMH and AFC, we opted to classify 
our included women based on the AMH level and because all included women in our study have been tested for 
AMH, but not for AFC. Furthermore, AMH was correlated with LH, FSH, testosterone, and androstenedione 
and this is likely to be attributed to the interaction of other hormones during the menstrual cycle. The age (nega-
tively correlated) and the AFC (positively correlated) were more significantly correlated with the AMH than to 
other markers and this is in agreement with the existing  literature1,47–51. Age is the single biggest factor affecting 
a woman’s chance to achieve pregnancy, and therefore age cannot be ignored in infertility research. It has been 
shown that a relevant portion of human miRNA changes depending on age and  sex52. In our study, age was highly 
correlated with the AMH level, but not with the miRNA abundance level of the validated miRNAs, and thus 
provide evidence that the alteration in miRNA abundance level was not linked to age, and most probably linked 
to the changes in AMH level. The AMH level was positively correlated with the abundance level of miRNAs in 
LAMH versus NAMH group and negatively correlated with the abundance level of miRNAs in HAMH versus 
NAMH group, indicating that when the AMH level decreases, the abundance level of the identified miRNAs 
decreases and when the AMH level increases, the miRNA abundance level also decreases. Accordingly, an abnor-
mal AMH level always leads to a reduction in the abundance level of miRNAs. This could explain the observed 
non-significant correlation and non-significant alteration in the miRNA abundance level in the screening and 
validation phases when the two abnormal groups (i.e., LAMH versus HAMH) were compared to one another. 
These findings suggest that miRNA abundance level is always reduced in case of an abnormal AMH level and 
probably in the cases with manifestations associated with diminished ovarian reserve. Based on these findings 
it is, however, premature to draw such a conclusion, as the number of included subjects in each group is too low.
One of the primary goals of this study was to find a diagnostic biomarker that can assess a woman’s ovarian 
reserve and thus her fertility and to supplement or replace previously used biomarkers. The altered miRNAs that 
are correlated with AMH were therefore subjected to a ROC analysis, which allows a statement to be made about 
the quality of the miRNA as a biomarker. For this purpose, the AUC values  were determined and found greater 
than 0.5 in all validated miRNAs correlated with AMH in both comparison groups LAMH versus NAMH and 
HAMH versus NAMH. This means that the miRNAs identified in the LAMH versus NAMH group can predict 
a low AMH level and thus a low ovarian reserve. MiRNAs identified as biomarkers in HAMH versus NAMH 
can predict a high AMH level and thus a high ovarian reserve. MiRNAs identified in both groups can predict 
abnormal AMH levels or abnormal ovarian reserve. The miRNAs, which can predict either low or high ovarian 
reserve, would tend to be more useful as biomarkers based on the information about the current state of the 
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ovarian reserve. The best AUC value was determined for the miR-100-5p. It indicates with a probability of 76% 
that the ovarian reserve is higher than normal.
In summary, the alteration in miRNA abundance level is in part associated with female reproduction and 
with diseases that affect female fertility status, and other miRNAs were newly identified in this area, suggesting 
that some miRNAs are involved in the maintenance of female fertility and changes of some other miRNAs might 
adversely and /or negatively affect female fertility. Altered abundance levels of miRNAs, particularly miR-100-5p, 
can provide new insights into the underlying mechanisms of female fertility and thus improve the diagnosis and 
treatment of infertility. The identified and validated miRNAs in our study should be further validated in a larger 
number of samples to confirm their predictive ability as biomarkers that could complement or possibly replace 
the previous markers as genetic biomarkers.
Methods
Study population and sample collection. Blood samples were collected from a total of 159 consecutive 
women undergoing infertility treatment with IVF-ICSI at Saarland University School of Medicine IVF Center 
(Homburg/Saar) between November 2016 and May 2020. The mean age was 32 ± 4.8 years (range 20–44 years). 
At enrollment, ultrasonography was conducted on the second day of the menstrual cycle to evaluate the anatom-
ical characteristics of the female reproductive system and determine the antral follicular count (AFC). Peripheral 
blood samples were then collected from each woman into serum tubes and PAXgene blood tubes (Becton–Dick-
inson, Heidelberg, Germany) on the third day of the menstrual cycle. The serum was immediately prepared by 
centrifugation at 1800g for 15 min and used to determine the level of Free Thyroxine 4 (FT4), Thyroid-Stimu-
lating Hormone, Prolactin (PRL), Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), Estradiol 
(E2), Testosterone, Androstenedione, Dehydroepiandrosterone Sulfate (DHEA-S), and anti-Müllerian hormone 
(AMH). All PAXgene blood tubes were stored at room temperature for at least 24 h to ensure complete lysis of 
the blood cells, then stored at − 20 °C for several days and finally transferred to − 80 °C for long-term storage 
until RNA including miRNA isolation. This study was approved by the Saarland University Institutional Review 
Board committee (Ärztekammer des Saarlandes Nr. 160/15) and informed consent was obtained from each 
participant and the study complies with the Declaration of Helsinki.
The determination of miRNA abundance levels was performed in three successive phases as indicated in 
Fig. 1. In phase I (screening phase), samples were randomly grouped based on their AMH level into low AMH 
level (LAMH, n = 12), normal AMH level (NAMH, n = 13), and high AMH level (HAMH, n = 13).
These samples were used to identify the differential miRNA abundance level by applying a miRNA microar-
ray. In phase II (validation of the screening phase), the initially identified miRNAs (phase I) were evaluated, 
by RT-qPCR assay. In phase III (Validation of the independent cohort), the selected miRNAs in phase II were 
additionally validated by RT-qPCR in an independent set of samples from 27, 67, and 27 women from the low, 
normal, and high level of AMH, respectively.
Isolation of total RNA, including miRNAs. Total RNA including miRNAs was isolated from blood 
samples using PAXgene Blood miRNA Kit on the QIAcube robot (Qiagen, Hilden, Germany) following the 
manufacturer’s recommendations. DNase I treatment (Qiagen, Hilden, Germany) was carried out during the 
isolation to eliminate any genomic DNA contamination as previously  described9. The total RNA concentra-
tion was measured using the NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Massachusetts, 
United States). RNA purity was assessed by determining the OD 260/280 and the OD 260/230 ratios. The qual-
ity of total RNA was assessed using the Agilent Bioanalyser 2100 Eukaryote Total RNA Nano Series II (Agilent 
Technologies, California, United States).
MiRNA microarray. MiRNA expression profiles in LAMH, NAMH, and HAMH were determined by 
hybridization to the Sureprint G3 Human v21 miRNA microarray chips, 8 × 60 K (release 21.0), each containing 
2549 human miRNAs (Agilent Technologies). Hybridizations were carried out following the manufacturer’s rec-
ommendations. In brief, 120 ng RNA from each sample was processed using the miRNA Complete Labeling and 
Hybridization Kit (Agilent Technologies) to generate fluorescence-labeled miRNA. The microarrays were loaded 
and incubated at 55 °C for 20 h with rotation. After several washing steps, microarrays were scanned with the 
Agilent Microarray Scanner at 3 microns in double path mode. Data was acquired using Agilent AGW Feature 
Extraction software version 10.10.11 (Agilent Technologies).
Reverse transcription and quantitative real‑time PCR (RT‑qPCR) of miRNA. The abundance 
level of circulating miRNAs was quantified by RT-qPCR using the Biomark HD System (Fluidigm Corporation, 
California, United States) and the TaqMan microRNA Assays (Thermo Fisher Scientific) according to the as pre-
viously  described53. Briefly, complementary DNA (cDNA) was generated in 8 µL reactions by reverse transcrip-
tion of 350 ng total RNA using the TaqMan MicroRNA Reverse Transcription Kit and RT Primers Pool (10×) 
(Thermo Fisher Scientific). Following reverse transcription, 2.5 μL of the generated cDNA was preamplified by 
mixing 12.5 µL of TaqMan PreAmp Master Mix (2×) and 3.75 μL of PreAmp Primers Pool (10×) (Thermo Fisher 
Scientific) in 25 µL reaction volume. Following the preamplification of the cDNA, RT-qPCR was carried out 
with 96.96 Dynamic Array IFC for Gene Expression arrays (Fluidigm Corporation) as indicated in Fluidigm’s 
protocol (PN 68000130 E1). Briefly, every 10× Assays contained 3 µL TaqMan Primer Assay (20×) (a mixture 
of forward and reverse primers, and probe) (Thermo Fisher Scientific), and 3 µL Assay Loading Reagent (2×) 
(Fluidigm, PN 85000736). Sample Pre-Mix was prepared by combining 3 µL TaqMan Universal PCR Master 
Mix, no AmpErase™ UNG (2×) (Thermo Fisher Scientific), 0.3 µL GE Sample Loading Reagent (20×) (Fluidigm, 
PN 85000735), and 2.7 µL pre-amplified cDNA for each sample. Finally, 5 µL of each Assay and Sample Mix were 
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transferred into the appropriate inlets according to the Fluidigm’s recommendation. After loading, the array was 
placed in the Biomark HD instrument for quantification and detection using GT 96 × 96 Standard v1 PCR ther-
mal protocol. The data were analyzed with Real-Time PCR Analysis Software (Fluidigm Corporation) accord-
ing to Fluidigm’s recommendation. Negative control samples  (H2O) were included in the reverse transcription, 
preamplification, and amplification steps and were finally defined as those with Ct values ≥ 35 or undetermined.
Statistical analysis. Microarray images were scanned using the Feature Extraction Software (Agilent Tech-
nologies) and the extraction of data was carried out using GeneSpring GX software (version 14.9.1, Agilent 
Technologies). Microarray measurements were normalized using quantile normalization and the differential 
abundance levels of miRNAs were identified for each sample. An unpaired two-sample t test with Benjamini–
Hochberg correction for multiple testing was applied, and adjusted P value of < 0.05 was considered statistically 
significant. Fold change for the LAMH and HAMH groups was obtained with respect to the NAMH group. 
Consequently, the lower and higher abundant miRNAs with a fold change > 2 were considered for further stud-
ies. The diagnostic value for each validated miRNA was evaluated by receiver operating characteristic (ROC) 
curves analysis and subsequently the area under the ROC curve (AUC) was computed to assess the potential use 
of miRNA(s) as a biomarker. The relative quantitative method of  2−ΔΔCt was used to measure the dynamic change 
of selected validated miRNAs using RNU6B small nuclear RNA (snRNA) as an endogenous reference miRNA 
as previously validated for this type of  sample53–61. The correlation analysis was carried out by the Spearman 
correlation coefficient and the differences in clinical characteristics among the three tested groups i.e., LAMH, 
HAMH, and NAMH were analyzed by analysis of variance (ANOVA) and data was presented as mean ± standard 
deviation with a P value of < 0.05 was considered statistically significant.
Ethics approval. Institutional Review Board approval/Ethikvotum Ärztekammer des Saarlandes: Ethical 
vote No. 160/15.
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